Physician profile
Gary Barbin
NPI 1568436780
$2,487.50
in general payments reported to CMS, 2019-2025
22 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,815 · 2020: $378 · 2021: $119 · 2023: $21.62 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $524.95 | 2019 | |
| Amgen INC. | $275.33 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $171.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $152.67 | 2019 | |
| Merck Sharp & Dohme LLC | $150.37 | 2019 | |
| Pfizer INC. | $146.35 | 2019-2020 | |
| Astellas Pharma US INC | $131.24 | 2019 | |
| Allergan, INC. | $128.59 | 2019 | |
| Shockwave Medical, INC | $128.30 | 2025 | |
| Esperion Therapeutics, INC. | $119.42 | 2021 | |
| Radius Health, INC. | $109.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.34 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $81.19 | 2019-2020 | |
| Amarin Pharma, INC. | $76.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.38 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31.76 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.42 | 2025 | Qelbree |
| Exact Sciences Corporation | $21.62 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $12.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.00 | 2019 | |
| Lilly USA, LLC | $11.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Barbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.